The Cooper Companies, Inc. COO Fertility — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Cooper Companies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: The Cooper Companies, Inc.’s 10-Q, filed June 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Cooper Companies, Inc.'s fertility — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Cooper Companies, Inc.'s fertility — net sales?
- The Cooper Companies, Inc. (COO) reported fertility — net sales of $143.8M in Q1 2026.
- How has The Cooper Companies, Inc.'s fertility — net sales changed year-over-year?
- The Cooper Companies, Inc.'s fertility — net sales increased by 13.3% year-over-year, from $126.9M to $143.8M.
- What is the long-term trend for The Cooper Companies, Inc.'s fertility — net sales?
- Over 4 years (2021 to 2025), The Cooper Companies, Inc.'s fertility — net sales has grown at a 13.2% compound annual growth rate (CAGR), from $319.2M to $524.6M.
- What does fertility — net sales mean?
- The total revenue earned specifically from the company's fertility and reproductive health product segment.
- How do you interpret fertility — net sales?
- An increase indicates growing demand for fertility-related medical solutions and successful market penetration, while a decrease may signal competitive pressure or reduced clinical adoption of the segment's offerings.
- How does fertility — net sales compare across companies?
- Comparable to revenue metrics for specialized medical device or reproductive health segments at peer healthcare and life sciences companies.